在有效管理内分泌抵抗性乳腺癌中准ERα的Protacs
Anupriya Singh1, Roshni Khan1, Noora Amana Erachampatt1
1Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab, Bathinda, Punjab, India.
针对蛋白质溶解的嵌合体 (PROTACs) 提供了一种降解雌激素受体α (ERα) 的新方法,解决了当前治疗方法的局限性. 这一策略显示出在ERα阳性乳腺癌中克服内分泌抵抗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 雌激素受体α (ERα) 对于雌激素驱动的基因表达和生理过程至关重要.
- 传统的内分泌疗法,如SERM和SERD,面临着挑战,包括在ERα突变癌症中获得的耐药性和降低的疗效.
研究的目的:
- 审查蛋白质解析向化马体 (PROTACs) 降解ERα的作用机制,设计和应用.
- 突出结构-活性关系 (SAR) 研究和ERα向PROTACs的体外/体内数据.
主要方法:
- 审查关于PROTAC技术和ERα生物学的现有文献.
- 对针对ERα的PROTAC进行SAR研究和实验数据的分析.
- 讨论设计有效ERα降解剂的策略.
主要成果:
- PROTACs选择性和高效地降解ERα,提供下一代治疗策略.
- 埃拉克斯特兰的批准激发了对新型ERα降解剂开发的兴趣.
- 文献数据提供了关于设计更有效的PROTACs的见解.
结论:
- 在ERα阳性乳腺癌中,PROTAC是一种有前途的治疗策略,可以克服内分泌抵抗.
- 进一步开发针对ERα的PROTAC可以为乳腺癌患者推进治疗选择.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
